



RevealAI-Lung Demonstrates Clinical Benefit for Lung Nodules in the UK

Seattle, WA - November 12, 2025 - RevealDX, a leader in the characterization of lung nodules, announced publication of a retrospective validation study in *Clinical Radiology* in partnership with the Royal United Hospitals Bath NHS Trust.

The RevealDX product, RevealAI-Lung, characterizes nodules by producing a score called the Malignancy Similarity Index (mSI™) to assist Radiologists with the creation of follow-up recommendations. In [this](#) study, titled; “A CADx tool improves lung nodule risk stratification when compared to British Thoracic Society guidelines on routine CT”, the conclusion states that, “mSI significantly improved nodule classification in incidental lung nodules when combined with current best-practice BTS guidelines.”

This announcement follows a recent [announcement](#) by RevealDX that the company has received MDR Certification for the RevealAI-Lung product, making it the first device with claims for lung nodules that certifies it reduces time to diagnosis and reduces false positives.

“We are the first to look at the impact of mSI at stratifying risk of lung cancer in lung nodules identified on CT scans in routine clinical care in the UK National Health Service (NHS) setting. RevealAI-Lung demonstrated potentially important improvements in streamlining care compared to current evidence-based best practice using British Thoracic Society guidance. As we have made significant progress in treating and curing early stage lung cancer, this has the potential to help save more lives.” said lead investigator Dr. Jonathan Rodrigues, from Royal United Hospitals Bath NHS Foundation Trust.

This announcement comes alongside Lung Cancer Awareness Month, taking place in November to raise public knowledge about the disease and encourage early detection and prevention. As a part of the company’s commitment to advancing lung health, RevealDX will also be exhibiting at the RSNA Meeting in booth #5121 beginning November 30, 2025.

Chris Wood, RevealDX CEO, said “This adds to the growing body of evidence for the benefit and generalizability of RevealAI-Lung. We’re excited to expand in the UK market and elsewhere where managing incidental lung nodules can benefit from enhanced risk stratification.”

The software can be purchased directly from RevealDX or through our exclusive EU distributor, [contextflow](#). The company previously announced it has integrated with Riverain, the leading US nodule detection company, and has partnered with Sirona, the leader in cloud native PACS.



Please note: This device is not FDA cleared and is intended for use in markets with EU MDR compliance. For more information, contact sales@reveal-dx.com.

About RevealDx

RevealDx has developed RevealAI-Lung, the world's first CADx software for the characterization of lung nodules to receive the CE Mark and Health Canada Approval, is registered with the MHRA (UK) and has TGA certification (AUS/NZ). The company has [published](#) several studies demonstrating significant improvement in both early cancer detection as well as reduction in false positive nodules. Studies show that by integrating this patented technology into routine clinical use, healthcare providers can more effectively triage lung nodules. <https://reveal-dx.com/>

Dr. Jonathan Rodrigues, MBChB(Hons), FRCR (UK), PhD is a

Consultant Cardiothoracic Radiologist, Royal United Hospitals Bath, and, Chief Scientific Officer, The HLH Imaging Group.

RevealAI-Lung was provided free of charge for this study to the RUH Bath. No other financial support or relationship exists between RevealDx and the investigator or RUH Bath.